In a secondary analysis of 97 opioid-using participants with HIV in the St PETER HIV trial, nicotinic partial agonists (varenicline, cytisine) vs nicotine replacement therapy did not significantly change self-reported opioid use at 1, 3, 6 or 12 months.
Secondary analysisn = 97
Rich et al. Assessing the impact of nicotinic partial agonists compared to NRT on opioid and cigarette use: A secondary analysis investigating treatment outcomes for co-occurring nicotine and opioid use